Novartis AG (NVS) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Novartis AG (NYSE:NVS) released its quarterly earnings results on Tuesday. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.04, MarketWatch Earnings reports. The business had revenue of $12.41 billion during the quarter, compared to the consensus estimate of $12.21 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.23 EPS.
Novartis AG (NYSE:NVS) opened at 85.91 on Tuesday. The stock’s 50 day moving average price is $85.66 and its 200-day moving average price is $82.41. The firm has a market cap of $201.28 billion, a PE ratio of 31.37 and a beta of 0.73. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90.
COPYRIGHT VIOLATION NOTICE: “Novartis AG (NVS) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/24/novartis-ag-nvs-issues-quarterly-earnings-results-beats-expectations-by-0-04-eps.html.
A number of analysts have recently weighed in on NVS shares. Zacks Investment Research downgraded Novartis AG from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, August 29th. Credit Suisse Group downgraded Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price for the company. in a research report on Wednesday, July 5th. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a research report on Wednesday, July 26th. Finally, Cowen and Company set a $77.00 target price on Novartis AG and gave the company a “hold” rating in a research report on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $85.28.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.